Stocktoria
Bicara Therapeutics Inc. BCAX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-09-13
Bicara Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | — | $63.6M | $30.6M |
| Operating income | -$155.6M | -$82.4M | -$39.9M |
| Income tax | $217,000 | $187,000 | $5,000 |
| Net income | -$137.9M | -$68.0M | -$52.0M |
| EPS (diluted) | $-2.52 | $-4.05 | $-89.61 |
| Operating cash flow | -$106.8M | -$74.8M | -$45.6M |
| Free cash flow | -$107.1M | -$74.8M | -$46.2M |
| Cash & equivalents | $96.7M | $489.7M | $230.4M |
| Total assets | $431.0M | $510.0M | $234.0M |
| Total liabilities | $29.5M | $18.1M | $15.5M |
| Shareholders' equity | $401.5M | $491.9M | -$148.8M |
Source: SEC EDGAR filings · CIK 0002023658 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.